Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1

Jennifer Vandooren, Wannes Swinnen, Estefania Ugarte-Berzal, Lise Boon, Daphne Dorst, Erik Martens and Ghislain Opdenakker

Laboratory of Immunobiology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, KU Leuven, Belgium.

ABSTRACT

Lipoplysaccharides or endotoxins elicit an excessive host inflammatory response and lead to life-threatening conditions such as endotoxemia and septic shock. Lipopolysaccharides trigger mobilization and stimulation of leukocytes and exaggerated production of pro-inflammatory molecules including cytokines and proteolytic enzymes. Matrix metalloproteinase-9 (MMP-9) or gelatinase B, a protease stored in the tertiary granules of polymorphonuclear leukocytes, has been implicated in such inflammatory reactions. Moreover, several studies even pinpointed MMP-9 as a potential target molecule to counter excessive inflammation in endotoxemia. Whereas the early effect of lipopolysaccharide-induced inflammation in vivo on the expression of MMP-9 in various peripheral organs has been described, the effects on the bone marrow and during late stage endotoxemia remain elusive. We demonstrate that TIMP-free MMP-9 is a major factor in bone marrow physiology and pathology. By using a mouse model for late-stage endotoxemia, we show that lipopolysaccharides elicited a depletion of neutrophil MMP-9 in the bone marrow and a shift of MMP-9 and MMP-9-containing cells towards peripheral organs, a pattern which was primarily associated with a relocation of CD11bhighGr-1high cells. In contrast, analysis of the tissue inhibitors of metalloproteinases was in line with a natural, systematic upregulation of TIMP-1, the main tissue inhibitor of TIMP-free MMP-9, and a general shift toward control of matrix metalloproteinase activity by tissue inhibitors of metalloproteinases.

Introduction

The regulation of leukocytosis is a balance between the exit of leukocytes into the periphery and the production of these cells in the bone marrow. Within this compartment systemic cytokine levels orchestrate a regulated response to peripheral signals, leading to leukocyte expansion through the action of colony-stimulating factors. At the molecular level this is translated into oligosaccharide-lectin interactions, expression of cell adhesion molecules, balances between proteases and inhibitors, and chemokine-mediated leukocyte recruitment to specific body compartments. Interference at any of these levels could represent a possible treatment for acute inflammatory reactions such as shock syndromes. An often explored strategy is interference with balances between proteases and inhibitors, for example, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). MMPs are named after their ability to degrade extracellular matrix proteins, namely gelatinases (MMP-2/9), collagenases (MMP-1/8/13), stromelysins (MMP-3/10/11) and others, but are also able to degrade cell-surface and intracellular molecules. One particular MMP implicated in cell mobility in and out of the bone marrow is MMP-9 or gelatinase B. MMP-9 is primarily produced by neutrophils, which pre-store large quantities of proMMP-9 (zymogen) in their tert-
ary granules (also called gelatinase granules) for swift release upon encounter with an inflammatory stimulus. When released in the bone marrow, activated MMP-9 processes membrane-bound Kit-ligand into soluble Kit-ligand and thereby keeps progenitor cells locally and initiates recruitment of "escaped" hematopoietic stem cells to their proliferative niche. In the periphery, MMP-9 contributes to the recruitment of bone marrow-derived neutrophils to the site of an inflammatory stimulus. It is not, therefore, surprising that studies involving mouse models for sepsis show beneficial outcomes for MMP-9-deficient mice and/or mice treated with MMP inhibitors. In the body, MMP proteolytic activity is kept in check by natural tissue inhibitors of metalloproteinases (TIMPs). While all four TIMPs (TIMP-1 to -4) have inhibitory activity on all MMPs, TIMP-1 preferentially binds to MMP-9 and TIMP-2 to MMP-2. A unique feature of TIMP-2 is that it can initiate the formation of a MT1-MMP/TIMP-2/proMMP-2 cell surface complex that aids the conversion of the proMMP-2zymogen into activated MMP-2. Similar to MMP-9, TIMP-1 is of importance in bone marrow physiology, in particular in the maintenance of hematopoietic stem cell quiescence and leukocytosis.

Lipopolysaccharides (LPS) or endotoxins are glycolipids present in the outer membrane of Gram-negative bacteria, and are released upon lysis of bacteria. In the body, LPS are detected as an alarm signal by leukocytes, endothelial cells and parenchymal cells through their LPS-receptor complex composed of myeloid differentiation factor 2 (MD2) and toll-like receptor 4 (TLR4), a process which is facilitated by LPS-binding protein (LB) and CD14. This interaction triggers cytokine production, leukocyte activation and inflammation, and excessive stimulation can lead to simultaneous activation of multiple parallel cascades that lead to adult respiratory distress syndrome and shock.

In this study we used injection of LPS as an animal model to study the mechanisms behind acute inflammation (endotoxia) caused by Gram-negative bacteria. Whereas the early effects of LPS in vivo on the expression of MMPs in various peripheral organs are known (Supplementary Table S1), effects on bone marrow and during late stages remain elusive. This is remarkable, given the importance of MMP-9 in leukocytosis and hematopoietic recovery. The aim of this study was to evaluate the effects of endotoxia on bone marrow gelatinases (MMP-2 and MMP-9) and, in parallel, the effect on their natural inhibitors. With the use of real-time polymerase chain reaction (qPCR), gelatin zymography and flow cytometry analysis, we demonstrated that endotoxia results in depletion of MMP-9 from the bone marrow. In parallel, this MMP-9 shift is complemented by systematic upregulation of TIMP-1. Finally, immunohistochemical analysis confirmed the migration of MMP-9-containing cells from the bone marrow to blood and peripheral organs.

Methods

Mouse model of endotoxia and sample collection

Endotoxia was induced in female 8-week old C57BL/6 mice by intraperitoneal (i.p.) injection of LPS (E. coli 0111:B4, Sigma Aldrich, L4951) at a dose of 10 mg/kg. Control mice were injected with an equal volume of vehicle (pyrogen-free phosphate-buffered saline, PBS; LPS level below 12.5 pg/mL). Twenty-four hours after injection, mice were sacrificed and organs were collected. Bone marrow cells were collected from femora by flushing the medullary cavity with PBS. Blood samples were collected by cardiac puncture with a heparin-coated needle and syringe, and immediately processed by centrifugation (2000 g for 10 min at 4°C). The supernatant (plasma) was collected and stored for protein analysis and the cell pellet was immediately processed for downstream analysis. Tissues were homogenized and proteins extracted with a Precellys lysing kit (Bertin Technologies), as described in the Online Supplementary Methods. All procedures were conducted in accordance with protocols approved by the local ethics committee (project number F201/2012, KU Leuven, Belgium).

Gelatin zymography

Protein levels of proMMP-9, MMP-9, multimeric MMP-9, proMMP-2 and MMP-2 were determined by gelatin zymography on affinity-purified samples, as previously described and detailed in the Online Supplementary Methods. Prior to zymography analysis, the total protein content was determined using a standard Bradford assay (Bio-Rad).

RNA expression analysis

RNA was extracted and equal amounts of RNA were converted to cDNA. qPCR was performed using TaqMan® fast universal PCR master mix (Applied Biosystems), PrimeTime® predesigned qPCR assays (IDT) and a 7500 Fast Real-Time PCR System (Applied Biosystems). Details, including primer specifications, are provided in the Online Supplementary Methods. The housekeeping gene Tbp was used as a calibrator for the relative quantification of gene expression. Normalization for Tbp and calculation of the relative expression was performed using the ΔACT method.

Immunohistochemistry

Femora were placed in 6% formaldehyde (1 day), decalcified in 7% formic acid (2 days) and embedded in paraffin. Paraaffin-embedded bones were sliced into 5 µm sections and dried overnight at 50°C. For immunohistochemical staining the EnVisionTM FLEX kit (DAKO) was used. Goat anti-mouse MMP-9 (R&D Systems) was used as the primary antibody. A detailed protocol is provided in the Online Supplementary Methods.

Flow cytometry analysis

Spleens and bone marrow were passed through cell strainers to obtain single cell suspensions. Red blood cells of spleen, bone marrow and blood cell suspensions were lysed with 0.83% NH4Cl. Cells were incubated with Fc-receptor-blocking antibodies anti-CD16/anti-CD32 (BD Biosciences Pharmingen, San Diego, CA, USA), Zumbi aguaBV510 (dead cell staining) (BioLegend, San Diego, CA, USA) and stained with anti-Gr1, anti-F4/80, anti-CD11b, anti-CD3 or anti-CD19 (eBioscience, San Diego, CA, USA). Cells were fixed and analyzed with a FACS Fortessa flow cytometer. Data were processed with the FlowJo software (Becton Dickinson Labware, Franklin Lakes, NJ, USA). A detailed protocol is provided in the Online Supplementary Methods.

Enzyme-linked immunosorbent assays and gelatin degradation assays

TIMP-1 and TIMP-2 concentrations were determined using mouse TIMP-1 (DY980) and TIMP-2 (DY63040-05) DuoSet enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems). To determine the gelatinolytic activity we used a previously described gelatin degradation assay. A detailed protocol is provided in the Online Supplementary Methods.
Statistical analysis

Data were analyzed using GraphPad Prism 7 software and are expressed as mean ± standard error of mean (SEM). Differences were determined using a Mann-Whitney test. Data were collected and confirmed over a course of five independent experiments with experimental groups ranging from two to six animals.

Results

The bone marrow compartment contains considerable levels of MMP-9 RNA and protein

Publicly available mRNA expression data of human and mouse tissues reveal that gene expression levels of MMP-9 are highest in bone and bone marrow of humans and mice (Figure 1A). We, therefore, first evaluated the baseline levels of MMP-9 protein in bone marrow, spleen, lungs, liver and plasma by using gelatin zymography. The main source of MMP-9 (here a combination of high-molecular weight proMMP-9 and MMP-9) was indeed the bone marrow (Figure 1B and Online Supplementary Figure S1), with bone marrow MMP-9 representing over 0.1% of the total bone marrow protein. Mean MMP-9 protein levels in bone marrow, spleen, lungs, liver and plasma were respectively 1131±212.8 ng/mg protein, 168.4±29.8 ng/mg protein, 49.1±4.9 ng/mg protein, 2.12±0.26 ng/mg protein and 0.6±0.09 ng/mg protein (mean±SEM, n = 5-10).

Endotoxemia results in a shift of the Mmp2/9 and Timp1/2/3 expression pattern

Acute inflammation was induced by i.p. injection of endotoxin. To follow hematologic changes during late stages, samples were collected from bone marrow, blood and spleen 24 h after LPS/PBS injection. Liver and lungs, two organs prone to dysfunction during endotoxemia and sepsis syndromes were also collected. Analysis of RNA expression of Mmp9, Mmp2, Timp1, Timp2, Timp3 and Timp4 in these tissues revealed a shift in the expression pattern of both gelatinases and TIMPs (Figure 2). In the bone marrow, the basal expression level of Mmp9 RNA was reduced by endotoxemia, while Mmp9 expression in liver and lungs increased significantly. In blood cells a trend toward increased Mmp9 expression was seen, while Mmp9 mRNA levels in the spleen remained unaltered. Interestingly, although the effect of endotoxemia on Mmp2 mRNA was less pronounced, it generally was opposing the expression pattern of Mmp9. Steady-state Mmp2 mRNA levels were increased in the bone marrow upon induction of endotoxemia, while expression in the spleen and lungs was decreased. While basal Timp1 expression was low, endotoxin triggered a considerable systematic induction. For Timp2 the opposite effect occurred, namely, a general downregulation. A significant alteration in Timp3 expression was found in bone marrow (upregulation) and liver (downregulation) while Timp4 expression remained low and unaltered. All four TIMPs are thus differently regulated in response to LPS.

Endotoxemia shifts MMP-9 from bone marrow to the circulation and peripheral organs

Biological samples contain complex mixtures of forms of MMP-2 and MMP-9 proteins. A first level of complexity lies in the fact that both proteases are produced as inactive pro-enzymes, proMMP-2 and proMMP-9. Activation of these pro-forms into active enzymes requires proteolytic removal of the pro-peptide by other proteases (to form MMP-2 and MMP-9) or chemical modification of the pro-peptide cysteine thereby disturbing the pro-peptide/active site interaction. These processes are fine-tuned and require a local environment favoring MMP activation. A second level of complexity involves the formation of high-molecular weight disulfide linked MMP-9 multimers, including MMP-9 trimers. Detailed analysis of these forms provides better insights into the dynamics of protease activity and can be performed using gelatin zymography analysis (Figure 3A). In Table 1, protein data for
MMP-2 and MMP-9 forms are provided for bone marrow, liver, lungs, spleen and plasma from healthy mice and mice with endotoxemia. As expected, basal levels of all MMP-9 forms were highest in the bone marrow followed by, respectively, spleen, lungs, liver and plasma. Highest levels of proMMP-2 were detected in lungs, followed by spleen and liver. MMP-2 was not detected in bone marrow, due to an overlap effect of the high quantities of MMP-9. Similarly, proteolytically activated MMP-9 could not be detected in bone marrow due to the overlap effect of proMMP-9. While proteolytic activation of MMP-9 probably occurs in this compartment, we could not detect this due to the high levels of proMMP-9 within this compartment. In plasma, MMP-2 levels were below the detection limit but proMMP-2 was detected. Upon induction of endotoxemia, drastic changes occurred in MMP-9 protein levels. The most severe changes were observed in the bone marrow, where protein levels of proMMP-9 and multimeric MMP-9 dropped by approximately 90% or, respectively, around 500 and 600 ng/mL (Table 1 and Figure 3B). This drop was much more pronounced in the bone marrow compartment. Taken together, we could not detect this pattern were observed in the LPS-stimulated samples. With the limitations of the resolution and sensitivity of this technique, we can conclude that no major charge modifications occurred upon induction of endotoxemia.

Systematic induction of TIMP-1 and reduction of TIMP-2

MMP activity is based on a balance between MMPs and their natural inhibitors. We, therefore, analyzed TIMP-1 and TIMP-2 protein levels. Basal levels of TIMP-1 and TIMP-2 were highest in the lungs (Table 2). Interestingly, basal levels of TIMP-1 in bone marrow were low while TIMP-2 was well represented. Next, LPS challenge resulted in a systematic change in TIMP-1 protein levels (Figure 4A). In agreement with RNA expression data, TIMP-2 was significantly decreased by LPS in bone marrow and spleen. In sharp contrast, endotoxemia induced the production of TIMP-1 in all organs, an effect which was most pronounced in the bone marrow compartment. Taken together, with a decrease in MMP-9 of approximately 90% and an almost 8-fold increase of TIMP-1, the effect of endotox-
Figure 2. The effects of endotoxemia on Mmp9, Mmp2, Timp1, Timp2, Timp3 and Timp4 RNA expression. Relative RNA expression in bone marrow, spleen, lungs, liver and blood cells of LPS-treated mice in comparison with the control group given PBS. Data were normalized for the housekeeping gene Tbp. Histograms represent group medians and individual data points from single animals are shown by dots. *P<0.05, **P<0.01, as determined by the Mann-Whitney test (n = 3-6).
Figure 3. Gelatin zymography analysis of the protein levels of MMP-9 and MMP-2 forms. (A) Representative gelatin zymography gels of bone marrow, spleen, lungs, liver and plasma of mice treated with LPS versus control mice (PBS). Each lane represents the analysis of the sample from a single mouse (n = 3-4). Each sample was spiked with an internal processing and loading control (MMP-9ΔHemOG – MMP-9 form lacking the C-terminal hemopexin and O-glycosylated domain) and each gel has three lanes of recombinant MMP-9 standard protein (RS), including multimeric, monomeric and MMP-9ΔHemOG proteins, to serve as a molecular weight marker and standard (10, 5 and 3 pg). The loading quantity of the samples corresponded to, respectively, 0.4 mg (bone marrow), 2 mg (spleen), 4 mg (lungs), 60 µg (liver) and 30 mg (plasma) of total protein. (B) Detailed analysis of protein levels of MMP-9 multimers, proMMP-9 monomers, activated MMP-9 monomers, proMMP-2 and activated MMP-2. Protein quantity was expressed as nanograms of MMP in one milligram of total protein. (C) Percentages of multimeric MMP-9 out of total MMP-9. (D) Percentages of proteolytically activated MMP-9 out of total MMP-9. (E) Percentages of proteolytically activated MMP-2. Histograms represent group medians and individual data points are shown by dots, each representing data from a single mouse. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, as determined by the Mann-Whitney test.
Table 2. Levels of TIMP-1 and TIMP-2 detected in bone marrow, spleen, liver and lungs.

|          | TIMP-1         | TIMP-2         | MMP-9/TIMP-1 | MMP-2/TIMP-2 |
|----------|----------------|----------------|--------------|--------------|
| Bone marrow | 0.003±0.006 | 2.48±0.49 | 102167 | ND |
| LPS      | 0.23±0.07 | 0.41±0.07 | 146 | ND |
| P        | **           | **           |   |   |
| Spleen   | 0.15±0.06  | 1.61±0.62  | 196 | 1.53  |
| LPS      | 0.98±0.41  | 0.98±0.23  | 28.9 | 1.97  |
| P        | **           | *            |   |   |
| Lungs    | 17.53±4.56 | 8.77±2.02 | 3.42 | 0.73  |
| LPS      | 4.12±1.09  | 8.84±1.29  | 1.43 | 0.82  |
| P        | **           | ns           |   |   |
| Liver    | 1.32±0.53  | 0.41±0.41  | 0.44 | 1.28  |
| LPS      | 4.20±2.66  | 0.83±0.82  | 0.36 | 0.62  |
| P        | *            | ns           |   |   |

Data are shown as mean±SD and are expressed as nanogram of TIMP per milligram of tissue protein (ng/mg) as determined by ELISA. Control mice (PBS) were statistically compared with mice given i.p. LPS injection. The two last columns represent the molar ratios of MMP-9/TIMP-1 and MMP-2/TIMP-2, calculated based on data in Table 1 and Table 2, and taking into account the molecular weight of each of the proteins. Values higher than one represent an excess of MMPs compared to TIMPs. ND: no signal detected; ns: non-significant; *P<0.05, **P<0.01 as determined by the Mann-Whitney test; n = 56.

Changes in MMP-9 levels correlate with neutrophil migration patterns

Neutrophils are the main producers of MMP-9 and they are unique because they do not produce TIMP-1.3,28 This concept was elaborated in a pioneering study on angiogenesis in tumor biology, but seemingly also has relevance in bone marrow physiology. We, therefore, hypothesized that the TIMP-1/MMP-9 shift during endotoxemia might be due to neutrophil mobilization into the circulation and into peripheral organs. To investigate this, we performed flow-cytometry analysis of bone marrow, spleen and blood cells to study the migration pattern of T cells (CD3+), B cells (CD19+), neutrophils (CD11b+Gr1+) and macrophages (CD11b+F4/80+) in animals with and without LPS injection (Figure 5). Indeed, in the bone marrow a significant decrease (from 52% to 34%) in the CD11b+Gr-1+ population of neutrophils was seen with LPS (Figure 5A,B). In addition, a shift of this population occurred towards the peripheral blood circulation, from 7% to 34% CD11b+Gr-1+ cells. Interestingly, endotoxemia also caused a reduction in splenic macrophages (CD11b+F4/80+ cells: from 2% to 1%) and a decrease in circulating B cells (CD19+ cells: from 36% to 15%). In addition, we evaluated the RNA expression of myeloperoxidase (MPO) and neutrophil elastase (ELANE), two molecules most abundantly expressed by neutrophils and hence functioning as neutrophil markers, in bone marrow, spleen, blood, liver and lungs. Overall, the relative RNA expression of the neutrophil markers Mpo and Elane followed a similar pattern as that for MMP-9, except in the spleen, where a significant decrease was seen in both Mpo and Elane expression upon induction of endotoxemia.

Immunohistochemical analysis of MMP-9

Next, we examined the tissue location of MMP-9 by immunohistochemistry. In the bone marrow, total staining for MMP-9 was markedly reduced in the animals administered LPS (Figure 6A). In addition, the immunoreactive staining was clearly confined to single cells which appeared as polymorphonuclear cells. In control mice (given PBS) these cells were diffusely found across the bone marrow while in endotoxemic conditions more cells were associated with the vasculature. In lungs (Figure 6B) and liver (Figure 6C) the opposite phenomenon occurred. While the baseline level of MMP-9-immunostained cells was low and predominantly restricted to blood vessels, LPS injection caused MMP-9-positive cells to migrate from blood vessels into lung alveoli, bronchioles and liver parenchyma. Again, staining was associated with polymorphonuclear cells. Spleen immunohistochemistry revealed a similar staining pattern for both the PBS and LPS conditions (Figure 6D). Generally, MMP-9-positive cells...
were located in red pulp, while no staining was seen in white pulp. In conclusion, immunohistochemical analysis of bone marrow, spleen, liver and lung sections further reinforced our data, showing decreased staining for MMP-9 in bone marrow, increased staining in liver and lungs, and no changes in the MMP-9 staining in spleen upon systemic in vivo challenge with LPS.

Discussion

Infection with Gram-negative bacteria accounts for about 60% of the bacterial infections causing sepsis, a disease associated with considerable lethality, even with the most sophisticated medical care. Previous studies suggest that MMP inhibition may become a treatment for endotoxin shock, although more in-depth preclinical work is necessary. In our model we used LPS, a Gram-negative bacterial component, to trigger endotoxemia and to study the distribution patterns of the two key gelatinases (MMP-9 and MMP-2) and their inhibitors (TIMPs). Since the time-dependent increase of MMP-9 during early pathology (1-12 h after induction of the syndrome) is well documented (Online Supplementary Table S1), our study was focused at a later stage of endotoxemia (24 h) and involved an in-depth analysis thereof. Whereas the importance of MMP-9 in the development of acute inflammation, such as sepsis syndrome, is evident from the beneficial effects observed with the use of MMP inhibitors, little is known about bone marrow gelatinases (MMP-9 and MMP-2) or the effects on the balance between MMPs and their natural inhibitors. Here we provide several new insights into this topic (Figure 7).

A first striking observation is the finding that MMP-9 accounts for more than 0.1% of total bone marrow protein, making MMP-9 an important factor in bone marrow

Figure 4. Systematic induction of TIMP-1 and reduced bone marrow MMP gelatinolytic activity. (A) TIMP-1 and TIMP-2 protein content in bone marrow, spleen, lungs and liver of mice injected i.p. with LPS or control mice (PBS injection) as determined by ELISA. Protein levels detected by ELISA were corrected for the total protein concentration and are presented as nanograms of TIMP in one milligram of total protein. (B) Degradation of fluorogenic gelatin by gelatinases present in bone marrow samples from mice treated with LPS and control mice, in the presence or absence of an inhibitor of MMP-2 and MMP-9 (SB-3CT, 10 μM) or elastase inhibitor (ElaV, 10 μM). The velocity of the gelatin degradation reaction was expressed as fluorescence units (FU) per minute and is indicative of the net proteolytic activity present in the samples. Inhibition percentages are shown. *P<0.05, **P<0.01, as determined by the Mann-Whitney test.
Physiology and pathology, for example in hematopoiesis. In addition, we show that during endotoxemia, the bone marrow is the major source of MMP-9 and that this MMP-9 is associated with polymorphonuclear cells. A limitation of the present study is that the analysis was performed at the single time-point of 24 h. Previous studies have shown that a peak in plasma MMP-9 occurs as early as 1-12 h after induction of sepsis and that MMP-9 is predominantly associated with neutrophils and late-stage maturing neutrophils such as band cells and segmented cells, present in the bone marrow. In our model of late endotoxemia (24 h), a significant shift in MMP-9 was still evident. In particular, we observed depletion of bone marrow MMP-9 and significant increases in MMP-9 in lungs and liver, while the spleen remained unaffected. This is in line with previous studies showing that patients suffering from sepsis have increased plasma levels of MMP-9 and that lungs and liver are indeed two highly affected organs during endotoxemia and sepsis syndromes. Parallel, we found that LPS induced mobilization of MMP-9-containing cells into the bloodstream. These cells predominantly migrated into lungs and liver, where clear infiltrations of MMP-9-positive cells were observed. We further confirmed this shift by showing a similar pattern for Gr-1 cells, which have been shown to contain large amounts of intracellular MMP-9.

MMPs are indeed known to aid cell migration because of their ability to degrade extracellular matrix molecules. This effect relies on direct proteolytic activity which is the result of a fine-tuned balance of protease levels, protease activation (the conversion of proMMP-9 into active MMP-9), and their natural inhibitors in endotoxemia.

Figure 5. MMP-9 levels relate with influx or efflux of a population of Gr-1 neutrophils. (A) Bone marrow, spleen and blood neutrophil content of mice not given an LPS injection (PBS, top) and given an LPS injection (bottom). Flow cytometry plots represent the distribution of live cells based on surface Gr-1 and CD11b staining. (B) Analysis of the T-cell (CD3+), B-cell (CD19+), neutrophil (CD11b+Gr1+) and macrophage (CD11b+F4/80+) populations in bone marrow, spleen, blood cells, liver and lungs of mice treated with PBS (control) or LPS. RNA expression data were normalized for the housekeeping gene Tbp. *P<0.05, **P<0.01, as determined by the Mann-Whitney test.
9 by proteolysis of the prodomain or chemical modification of the pro-peptide cysteine) and the presence of inhibitors (e.g. TIMP-1). An important new finding of our work is that, although MMP-9 increases systemically after LPS challenge, a natural anti-proteolytic response occurs by systematically increasing TIMP-1. This is evident from both tissue MMP-9/TIMP-1 ratios and proteolytic activity tests. In addition, the relative expression of Timp1 also considerably increased upon LPS challenge in almost all organs, including the bone marrow. These findings allowed us to address two questions: (i) whether inhibition of proteolysis by MMP-9 still has merit once acute inflammation has progressed (late-stage) and (ii) whether the contribution of TIMP-1 is disease-promoting or disease-limiting. Most animal studies, showing beneficial effects for MMP-9 inhibitors, were performed with inhibitor injections immediately after the induction of endotoxemia or in MMP-9 knock-out animals. In addition, higher serum levels of TIMP-1 have been found in non-survivors compared to survivors of severe sepsis. This confirms that the fine-tuned regulation of MMPs, including their balance with TIMPs, is crucial for tissue homeostasis. A good approach to the treatment of acute inflammations might, therefore, rely on carefully restoring this balance depending on the proteolytic state.

So far, the protease/anti-protease balance has been predominantly investigated in lungs and is key to normal lung physiology. The most studied example in lungs is the elastase/anti-elastase balance. This is exemplified by mouse models in which both induction of elastase and mutations of antitrypsin (elastase inhibitor) lead to emphysema. We here show that endotoxemia also drastically affects the lungs by inducing the accumulation of MMP-9-positive cells. Nevertheless, this effect is counterbalanced by induction of TIMP-1. Indeed, it was previously suggested that the pulmonary accumulation of neutrophils in sepsis is due to shedding of platelet-derived surface-expressed CD40L by MMP-9. Although TIMP-1 increases in bone marrow, most MMP-
9 (>99%) remains TIMP-free and thus potentially catalytically active. Indeed, neutrophils are unique in the fact that they do not secrete TIMP-1. Moreover, this TIMP-free MMP-9 was shown to have angiogenic capacity in particular when neutrophils infiltrate peripheral tissue or tumor microenvironments. In general, we show that bone marrow functioning relies on a combination of proteolysis by MMP-9 and neutrophil elastase and that both activities are reduced during late-stage endotoxemia. Previously it was shown that neutrophil elastase can compensate for MMP-9 deficiency in a model of leukocyte infiltration in experimental peritonitis. Neutrophil elastase is a serine protease found in the azurophilic granules of neutrophils. In contrast to MMP-9, neutrophil elastase knock-out mice have impaired host defense against Gram-negative bacterial sepsis. Neutrophil elastase can, therefore, also be considered as an important factor in endotoxin shock and requires further investigation.

To date, the management of acute systemic inflammation, such as sepsis in patients, is mostly limited to supportive care. Although targeting MMP-9 in these conditions has been suggested, it has been shown that MMP-9 inhibition has a limited therapeutic time window. During late-stage endotoxin shock, the host responds with systematic upregulation of TIMP-1 and shift in the protease/anti-protease balance towards reduced proteolysis. Together with reports showing higher levels of TIMP-1 in non-survivors and the present data on profound effects of LPS on MMP-9-laden neutrophils in the bone marrow, successful treatment of sepsis with protease inhibitors might first require detailed analysis of the protease/anti-protease balance in humans. Nevertheless, our study provides new insights, techniques and data to probe critical enzymes and inhibitors. In addition, it shows the technical limitations encountered during in-depth analysis of non-proteolytic MMP activation in a biological setting. A future aim for the treatment of endotoxin shock might be the containment of neutrophils in the bone marrow compartment for the purpose of prohibiting collateral damage in the tissues of peripheral organs.

**Funding**

The authors would like to thank KU Leuven for C1 grant support (C16/17/010) and the Research Foundation of Flanders (FWO-vlaanderen).
References

1. Opdenakker G, Fibbe WE, Van Damme J. The molecular basis of leukocytosis. Immunol Today. 1998;19(4):182-189.
2. Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016;15(5):551-567.
3. Hu J, Van den Steen PE, Sang OX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6(8):480-498.
4. Clark IM, Swingler TE, Sampieri CL, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9-mediated release of kit-ligand. Cell. 2002;109(5):625-637.
5. De Haese A, Wuyts A, Dillen C, et al. Requirement of stem and progenitor cells for bone marrow niche requires MMP-9. Mol Cell. 2002;109(5):625-637.
6. Masure S, Proost P, Van Damme J, et al. Substrate binding and activation of 72-kDa type IV collagenase. J Biol Chem. 1994;269(17):12153-12159.
7. Heissig B, Hattori K, Dias S, et al. Matrix metalloproteinase inhibitors attenuate endotoxin-induced protein S-glutathiolation via disulfide-oxidase. J Biol Chem. 2001;276(31):29596-29602.
8. Vandooren J, Geurts N, Martens E, Van den Steen PE, Opdenakker G. Beta-thromboglobulin A (β-TG) inhibition of gelatinase B/MMP-9 and protection against endotoxin shock. J Biol Chem. 2000;275(1):61-66.
9. Hu J, Van den Steen FE, Dillen C, et al. Targeting neutrophil collagenase by a recombinant glycation epitope. Nat Med. 1998;4(5):615-618.
10. Debruyne F, Van der Perre P, et al. Neutrophil elastase activity contributes to angiotensin I generation by human neutrophils. J Biol Chem. 1995;270(46):28095-28100.
11. Lalu MM, Gao CQ, Schulz R. Matrix metalloproteinase activity in lung microvascular endothelial cells. J Biol Chem. 2002;277(18):16022-16027.
12. Vandooren J, Born B, Solomonov I, et al. Circulating trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. J Biol Chem. 2005;280(25):25970-25977.
13. Zhou M, Jacob A, Ho N, et al. Down-regulation of protein disulfide isomerase in sepsis and its role in tumor necrosis factor-alpha release. Crit Care. 2008;12(4):R100.
14. Van den Steen FE, DuBois B, Nielsen I, et al. Neutrophil elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002-2006.
15. Rahman M, Zhang S, Chew M, Syk I, Jeppsson B, Thorlacius H. Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis. J Thorac Haemost. 2013;11(7):1385-1398.

J. Vandooren et al.